DOCSLIB.ORG

ACNP 58Th Annual Meeting: Keyword Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACNP 58Th Annual Meeting: Keyword Index www.nature.com/npp ABSTRACTS COLLECTION ACNP 58th Annual Meeting: Keyword Index Key Word ........................................................................ Submission Number(s) Adolescent PTSD ......................................................................................................T83 1H MRS .............................................................................................M135, M189, W8 Adolescent Stress ...................................................................................T277, W259 22q11.2 CNV ..............................................................................................................T12 Adolescents .................................................................................... T108, T266, W50 24(S)-hydroxycholesterol ..................................................................................M147 adrenal .........................................................................................................................53.4 25-hydroxycholesterol .......................................................................................... 54.5 adult ............................................................................................................................ T256 4-chlorokynurenine (AV-101) .......................................................................... T161 adult anxiety ..............................................................................................................T71 5-HT1A receptors ................................................................................................ W280 adult hippocampal neurogenesis ............................................................... W146 5-ht1b ......................................................................................................................... T177 adult neurogenesis ............................................................................................ W131 5-HT2CR ...................................................................................................................... W66 Adult stem cells ....................................................................................................M206 5HT5A receptor antagonist ........................................................................... W189 adverse childhood experiences (ACE) .............................................. T93, T102 7T fMRI ......................................................................................................... W16, W280 Advocacy ....................................................................................................................... 15 ABCD study ..............................4, 35.3, M36, M53, M59, M154, W41, W236 affective components of pain ................................................................................ 6 abstinence .............................................................................................................. W262 affective disorders .......................................................... 23, 28, M56, T72, T131 Abuse Liability ...................................................................................................... W220 affective instability .................................................................................................32.3 acamprosate .......................................................................................................... W272 affective response control ...............................................................................M110 accelerated aging .................................................................................................... T85 African Americans ................................................................................... 13.3, M220 1234567890();,: acetylcholine ............................................................. 37.2, 37.4, W4, W15, W264 age .................................................................................................................................. T95 Acetyl-L-carnitine LAC ................................................................... 2.3, T142, W89 age effects .......................................................................................................26, M167 Actigraphy ................................................................................................................. M33 Ageing .............................................................. 26.3, 46.3, M110, T66, T69, T257 Action-outcome associations ............................................................................... 44 aggression ....................................................................................... T249, T251, W38 activated microglia .................................................................................................T36 aging ....................................................50, 57, M4, T68, T227, W5, W98, W120 Active Avoidance ................................................................................................ W212 Aging and dementia ...............................................................................................W4 Activity-based anorexia ...................................................................................... W69 Agitation ....................................................................................................... M72, T230 Acute agitation .................................................................................................... W192 Alcohol .................................................. 17.1, 40.2, M170, M211, M215, M247, Acute and Chronic Stress ....................................M128, T58, T68, T90, T117 M252, M254, M263, M269, M276, T49, T112, T235, T242, T249, T255, T271, W51, W227, W236 Acute Stress ..................................................................................... 23, M125, M133 alcohol relapse treatment ................................................................ M251, W247 Acute Traumatic Stress ........................................................................................... T7 alcohol abuse ......................................................................................................... T240 Adaptive Behavior ...............................................................................................M257 Alcohol and substance use disorders ............................. 25.5, M255, T116, addiction ..................................................... 9, 23, 25.2, 31, 31.4, 52, 56, M230, T159, T238, T239, W240, W276 M255, T48, T49, T54, T241, W241, W262, W271 Alcohol consumption ............................................. M240, T240, W233, W265 addiction circuitry ...............................................................................................M248 Alcohol dependence ......................................M63, T61, W226, W238, W265 Addiction phenotypes ................................................................... 31.3, 31.4, 52.4 alcohol drinking ......................................................................... M261, T118, T250 adenosine A2A receptor ....................................................................................... 9.4 Alcohol epigenetic marks ...................................................................T261, W233 adenosine monophosphate activated protein kinase (AMPK) ....................................................................................................... W242 alcohol self-administration ..................................M253, M260, W247, W251 Adenosine signaling .......................................................................................... W217 Alcohol Sensitivity ...................................................................... T250, T251, T257 adenylyl cyclase ................................................................................................... W129 alcohol use disorder ...........................................................10.3, 31.4, 40, M246, M251, M253, T47, T51, T56, T236, T241, ADHD ............................................................................................... T108, W55, W114 T251, T256, T272, W229, W268, W270, W272, W275 Adjunctive therapy ............................................................................................... M86 alcohol use disorders .......................................................................................... T240 ADL ..................................................................................................................................W1 alcohol withdrawal .............................................................................................M251 Adolescence ..................................................29.4, 35.2, M43, M49, M57, M61, alcohol withdrawal syndrome ........................................................................ T248 M62, M138, M242, T42, T53, T84, T242, fl T278, T280, W194, W246, W249 alcohol-induced in ammation ..................................................................... W270 Adolescent ...................................... M46, M231, T72, T128, W41, W59, W93 Alcoholism ................................................................................................... T246, T253 Adolescent Alcohol ................................................................................T258, W261 Alcohol-seeking behavior ................................................................................M243
Load more

Recommended publications
  • Heater Element Specifications Bulletin Number 592
    Technical Data Heater Element Specifications Bulletin Number 592 Topic Page Description 2 Heater Element Selection Procedure 2 Index to Heater Element Selection Tables 5 Heater Element Selection Tables 6 Additional Resources These documents contain additional information concerning related products from Rockwell Automation. Resource Description Industrial Automation Wiring and Grounding Guidelines, publication 1770-4.1 Provides general guidelines for installing a Rockwell Automation industrial system. Product Certifications website, http://www.ab.com Provides declarations of conformity, certificates, and other certification details. You can view or download publications at http://www.rockwellautomation.com/literature/. To order paper copies of technical documentation, contact your local Allen-Bradley distributor or Rockwell Automation sales representative. For Application on Bulletin 100/500/609/1200 Line Starters Heater Element Specifications Eutectic Alloy Overload Relay Heater Elements Type J — CLASS 10 Type P — CLASS 20 (Bul. 600 ONLY) Type W — CLASS 20 Type WL — CLASS 30 Note: Heater Element Type W/WL does not currently meet the material Type W Heater Elements restrictions related to EU ROHS Description The following is for motors rated for Continuous Duty: For motors with marked service factor of not less than 1.15, or Overload Relay Class Designation motors with a marked temperature rise not over +40 °C United States Industry Standards (NEMA ICS 2 Part 4) designate an (+104 °F), apply application rules 1 through 3. Apply application overload relay by a class number indicating the maximum time in rules 2 and 3 when the temperature difference does not exceed seconds at which it will trip when carrying a current equal to 600 +10 °C (+18 °F).
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Pharmacogenetics of Ketamine Metabolism And
    Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Yibai Li B.HSc. (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide September 2014 A thesis submitted for the Degree of PhD (Medicine) Table of contents TABLE OF CONTENTS .............................................................................................. I LIST OF FIGURES ....................................................................................................IV LIST OF TABLES ......................................................................................................IV ABSTRACT ............................................................................................................... V DECLARATION .......................................................................................................VIII ACKNOWLEDGEMENTS ..........................................................................................IX ABBREVIATIONS .....................................................................................................XI CHAPTER 1. INTRODUCTION .................................................................................. 1 1.1 A historical overview of ketamine ........................................................................................ 1 1.2 Structure and Chemistry ....................................................................................................... 3 1.3 Classical analgesic mechanisms of ketamine ...................................................................
    [Show full text]
  • Opioid Withdrawal ��������������������������������������������������������������������������������������������������� 15 Mark S
    Magdalena Anitescu Honorio T. Benzon Mark S. Wallace Editors Challenging Cases and Complication Management in Pain Medicine 123 Challenging Cases and Complication Management in Pain Medicine Magdalena Anitescu Honorio T. Benzon • Mark S. Wallace Editors Challenging Cases and Complication Management in Pain Medicine Editors Magdalena Anitescu Honorio T. Benzon Department of Anesthesia and Critical Care Department of Anesthesiology University of Chicago Medicine Northwestern University Chicago, IL Feinberg School of Medicine USA Chicago, IL USA Mark S. Wallace Division of Pain Medicine Department of Anesthesiology University of California San Diego School of Medicine La Jolla, CL USA ISBN 978-3-319-60070-3 ISBN 978-3-319-60072-7 (eBook) https://doi.org/10.1007/978-3-319-60072-7 Library of Congress Control Number: 2017960332 © Springer International Publishing AG 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Specific PET-Ligands for Selected 5-Htand GABA A-Receptor Subtypes
    Specific PET-ligands for Selected 5-HT and GABAA-Receptor Subtypes PET-Liganden mit Spezifität für definierte 5-HT und GABAA-Rezeptor-Subtypen Dissertation zur Erlangung des Grades „Doktor der Naturwissenschaften“ am Fachbereich Biologie der Fabian Debus geb. am 19.09.1976 in Frankfurt am Main Mainz, im März 2008 Erklärung Hiermit versichere ich, dass ich die vorliegende Dissertation eigenständig verfasst und keine anderen als die angegebenen Hilfsmittel verwendet habe. Die Dissertation habe ich weder als Arbeit für eine staatliche oder andere wissenschaftliche Prüfung eingereicht noch ist sie oder ein Teil dieser als Dissertation bei einer anderen Fakultät oder einem anderem Fachbereich eingereicht worden. Mainz, im März 2008 II Dekan: 1. Berichterstatter: 2. Berichterstatter: Tag der mündlichen Prüfung: 28.05.2008 III Danksagung Eine solche Schrift kann niemals als Ergebnis der Arbeit eines Einzelnen, sondern sollte immer als Resultat der Arbeit einer großen Anzahl von fleißigen Menschen betrachtet werden, die dabei mitgeholfen haben, dass aus einer Idee ein gelungenes Projekt wurde. Bei meinen beiden Betreuern, Prof. Dr. H. L. und Prof. Dr. F. R., möchte ich mich für das spannende und abwechslungsreiche Thema bedanken. Außerdem für Ihr Vertrauen und Ihre Diskussionsbereitschaft. Insbesondere Herrn Prof. Dr. H. L. möchte ich für seine Unterstützung und seine vorbildliche Betreuung danken. Ich hätte mir keinen besseren Doktorvater wünschen können und bin sehr dankbar für alles, was ich in diesen drei Jahren in seiner Arbeitsgruppe lernen durfte. Besonderer Dank gebührt der gesamten Arbeitsgruppe für Ihre herzliche Gemeinschaft und das produktive Miteinander. Im Einzelnen gebührt Frau R. Dank für das Licht im Dunkel der Bürokratie. Frau B.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • LA Express Quick Ship Program
    EXPRESS VOLUME 3 SOFAS SECTIONALS CHAIRS BEDS FABRICS FOR HICKORY WHITE LA EXPRESS: LA6258S Hinson Sofa (see page 3) 70+ Frames 100+ Fabrics 4 to 6 Week Shipping FOR IN-STOCK FABRICS Our best-selling Lillian August sofas, chairs and beds are now able to be shipped in 20 working days from date of acknowledgment. Available in our most popular Designer Select fabrics, these combinations of fabric and frame are the tried and proven top performers. Mark all orders LA EXPRESS. Note: Standard throw pillows must be in a quick ship fabric and wood finish must be in a standard finish to receive all program benefits. Click on the photo of any product for more details. LA7116S Paris Sofa (shown) Loose pillow back (two) Overall: W97 D39 H35 Inside: W87 D22 H17 Arm height: 28 Seat height: 19 Standard pillows: two 21" throw pillows Standard with #1-P nail trim, spaced as shown. Standard with casters. Available in any standard finish. LA7113S Royce Court Sofa (shown) Loose pillow back (two) ALSO AVAILABLE: Overall: W87 D37 H37 Inside: W81 D20 H19 LA7116L Paris Loveseat Arm height: 23 Seat height: 19 Loose pillow back (two) Two seat cushions Overall: W67 D39 H35 Inside: W57 D22 H17 Dressmaker skirt Arm height: 28 Seat height: 19 Standard pillows: two 21" throw pillows ALSO AVAILABLE: Standard with #1-P nail trim. LA7113M Royce Court Mid Sofa Standard with casters. Loose pillow back (two) Available in any standard finish. Overall: W77 D37 H37 Inside: W71 D20 H19 Arm height: 23 Seat height: 19 LA7116M Paris Mid-Sofa Two seat cushions Loose pillow back (two) Dressmaker skirt Overall: W87 D39 H35 Inside: W77 D22 H17 Arm height: 28 Seat height: 19 LA7113C Royce Court Chair (see page 22) Standard pillows: two 21" throw pillows Standard with #1-P nail trim.
    [Show full text]
  • The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder
    REVIEW The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder Natalia del Campo, Samuel R. Chamberlain, Barbara J. Sahakian, and Trevor W. Robbins Through neuromodulatory influences over fronto-striato-cerebellar circuits, dopamine and noradrenaline play important roles in high-level executive functions often reported to be impaired in attention-deficit/hyperactivity disorder (ADHD). Medications used in the treatment of ADHD (including methylphenidate, dextroamphetamine and atomoxetine) act to increase brain catecholamine levels. However, the precise prefrontal cortical and subcortical mechanisms by which these agents exert their therapeutic effects remain to be fully specified. Herein, we review and discuss the present state of knowledge regarding the roles of dopamine (DA) and noradrenaline in the regulation of cortico- striatal circuits, with a focus on the molecular neuroimaging literature (both in ADHD patients and in healthy subjects). Recent positron emission tomography evidence has highlighted the utility of quantifying DA markers, at baseline or following drug administration, in striatal subregions governed by differential cortical connectivity. This approach opens the possibility of characterizing the neurobiological underpinnings of ADHD (and associated cognitive dysfunction) and its treatment by targeting specific neural circuits. It is anticipated that the application of refined and novel positron emission tomography methodology will help to disentangle the overlapping and dissociable contributions of DA and noradrenaline in the prefrontal cortex, thereby aiding our understanding of ADHD and facilitating new treatments. Key Words: Attention-deficit/hyperactivity disorder, dopamine, DA and NA in the pathophysiology of ADHD, with a focus on the frontostriatal circuits, nigrostriatal projections, noradrenaline, pos- molecular neuroimaging literature.
    [Show full text]
  • Fundamentals of C.R.P.S
    FUNDAMENTALS OF C.R.P.S. PHILIP GETSON, D.O. SEPTEMBER 11, 2015 R.S.D. Association National Conference I DON’T KNOW ! Philip Getson, D.O. October 22, 1999 Third National RSD Association Conference Atlantic City N.J. HISTORY The first mention of CRPS dates back to the 17th Century when surgeon Ambrose Pare reported that King Charles IX suffered from persistent pain and contracture of his arm following a bloodletting procedure During the Civil War Mitchell described soldiers suffering from burning pain due to gunshot wounds. He termed this Causalgia In 1900 Sudek described complications of trauma to the limbs with swelling, limitation of motor function and resistance to treatment The term Reflex Sympathetic Dystrophy was first used by Evans in 1946 NOMENCLATURE Causalgia Sudek’s Atrophy Post traumatic Pain Syndrome Post traumatic Painful Arthrosis Sudek’s Dystrophy Post Traumatic Edema Reflex Dystrophy Shoulder Hand Syndrome Chronic Traumatic Edema Algodystrophy Peripheral Trophoneurosis Sympathalgia Reflex Sympathetic Dystrophy Reflex Neurovascular dystrophy DEFINITION Complex Regional Pain is a neuropathic/inflammatory pain disorder characterized by: 1. Severe pain that extends beyond the injured area and is disproportionate to the inciting event. 2. Autonomic dysregulation 3. Edema – usually neuropathic in nature 4. Movement disorders 5. Atrophy and/or dystrophy CAUSE There is no single cause of CRPS Some more common are: sprain, contusion, surgery, fracture, infections, myocardial infarctions, carpel tunnel syndrome,
    [Show full text]
  • Product Data Sheet: Rosemount Volume 1 Temperature Sensors and Accessories (English)
    Product Data Sheet 00813-0100-2654, Rev KB July 2020 Rosemount™ Volume 1 Temperature Sensors and Accessories (English) ■ RTD and thermocouple offering in single and dual sensor models ■ Barstock thermowell offering in wide range of materials and process connections ■ Calibration capabilities for increased measurement accuracy ■ Sanitary RTD for hygienic applications Sensors and Accessories (Volume 1) July 2020 Feature and benefits Optimize plant efficiency and increase measurement reliability with industry- proven design and specifications ■ Available in a variety of sensing technologies – RTD and thermocouples ■ All sensor styles and lengths are available in ¼-in. diameter. ■ State-of-the-art manufacturing procedures provide robust element packaging, increasing reliability. ■ Industry-leading calibration capabilities allow for Callendar-Van Dusen values to give increased accuracy when paired with Rosemount transmitters. ■ Optional Class A accuracy for critical temperature measurement points. ■ Sanitary offering provides sensor assemblies approved for hygienic applications. Streamline operations and maintenance with sensor and thermowell design ■ Spring loaded threaded adapter, general-purpose welded adapter, capsule, and bayonet styles offer remote or integral transmitter mounting configuration Contents Feature and benefits..........................................................................................................................................................................2 Introduction.....................................................................................................................................................................................
    [Show full text]
  • Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events Christine Marie Emnett Washington University in St
    Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Winter 12-15-2014 Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events Christine Marie Emnett Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Biology Commons Recommended Citation Emnett, Christine Marie, "Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events" (2014). Arts & Sciences Electronic Theses and Dissertations. 347. https://openscholarship.wustl.edu/art_sci_etds/347 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Neurosciences Dissertation Examination Committee: Steven Mennerick, Chair James Huettner Daniel Kerschensteiner Peter D. Lukasiewicz Joseph Henry Steinbach Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events by Christine Marie Emnett A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy December 2014
    [Show full text]
  • And D2-Type Dopamine Receptors Are Linked to Motor Response Inhibition in Human Subjects
    5990 • The Journal of Neuroscience, April 15, 2015 • 35(15):5990–5997 Behavioral/Cognitive Striatal D1- and D2-type Dopamine Receptors Are Linked to Motor Response Inhibition in Human Subjects Chelsea L. Robertson,1,5 Kenji Ishibashi,3,4 Mark A. Mandelkern,5,6 Amira K. Brown,3 Dara G. Ghahremani,3 Fred Sabb,3 Robert Bilder,3 Tyrone Cannon,2 Jacqueline Borg,2 and Edythe D. London1,3,4,5 Departments of 1Molecular and Medical Pharmacology, and 2Psychology, 3Department of Psychiatry and Biobehavioral Sciences, The Semel Institute for Neuroscience and Human Behavior at UCLA, and 4Brain Research Institute, University of California, Los Angeles, Los Angeles, California 90024, 5Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California 90073, and 6Department of Physics, University of California, Irvine, Irvine, California 92697 Motor response inhibition is mediated by neural circuits involving dopaminergic transmission; however, the relative contributions of dopaminergic signaling via D1- and D2-type receptors are unclear. Although evidence supports dissociable contributions of D1- and D2-type receptors to response inhibition in rats and associations of D2-type receptors to response inhibition in humans, the relationship between D1-type receptors and response inhibition has not been evaluated in humans. Here, we tested whether individual differences in striatal D1- and D2-type receptors are related to response inhibition in human subjects, possibly in opposing ways. Thirty-one volunteers participated. Response inhibition was indexed by stop-signal reaction time on the stop-signal task and commission errors on the continuous performance task, and tested for association with striatal D1- and D2-type receptor availability [binding potential referred to 11 18 nondisplaceable uptake (BPND )], measured using positron emission tomography with [ C]NNC-112 and [ F]fallypride, respectively.
    [Show full text]